Parra-Guillen, Zinnia P <br/><br/>
Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.  [electronic resource] 

 -  Basic & clinical pharmacology & toxicology  Oct 2017 
 - 309-315 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1742-7843 
<br/><br/><label>Standard No.: </label>10.1111/bcpt.12801  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--adverse effects<br/>Caffeine--pharmacokinetics<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Chromatography, Liquid<br/>Cytochrome P-450 CYP1A2--genetics<br/>Cytochrome P-450 CYP3A--genetics<br/>Dried Blood Spot Testing<br/>Drug Monitoring--methods<br/>Erlotinib Hydrochloride--adverse effects<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Midazolam--pharmacokinetics<br/>Middle Aged<br/>Models, Biological<br/>Pharmacogenetics<br/>Pharmacogenomic Variants<br/>Phenotype<br/>Prospective Studies<br/>Protein Kinase Inhibitors--adverse effects<br/>Substrate Specificity<br/>Tandem Mass Spectrometry<br/>Treatment Outcome